Triple therapy shows promise for aggressive head and neck cancers
NCT ID NCT00875849
First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tested a combination of chemotherapy, radiation, and a targeted drug called cetuximab in 53 patients with head and neck cancer who had a high risk of the cancer coming back after surgery. The goal was to see if this triple therapy could keep the cancer from returning for at least two years. The approach aims to control the disease rather than cure it, as ongoing monitoring and potential further treatment are typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.